scholarly article | Q13442814 |
P356 | DOI | 10.1007/S12032-007-0035-7 |
P698 | PubMed publication ID | 17917094 |
P50 | author | Mustafa Benekli | Q56435446 |
P2093 | author name string | Suleyman Buyukberber | |
Ugur Coskun | |||
Mustafa Dikilitas | |||
Aytug Uner | |||
Ali Osman Kaya | |||
Banu Ozturk | |||
Emel Yaman | |||
Ramazan Yildiz | |||
Deniz Yamac | |||
Ozlem Er | |||
Mevlude Polat | |||
P2860 | cites work | Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108. | Q46538590 |
Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study | Q46648452 | ||
Capecitabine plus oxaliplatin (xelox) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: a GOAM phase II randomised study (FOCA trial) | Q56996728 | ||
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial | Q28036747 | ||
Cancer statistics, 2007 | Q29547293 | ||
A phase II study of capecitabine plus oxaliplatin (XELOX): a new first-line option in metastatic colorectal cancer | Q33366181 | ||
XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer | Q33370632 | ||
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer | Q33913953 | ||
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer | Q33978749 | ||
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study | Q34514696 | ||
Capecitabine plus oxaliplatin vs infusional 5-fluorouracil plus oxaliplatin in the treatment of colorectal cancer. Pro: The CapeOx regimen is preferred over FOLFOX. | Q36259006 | ||
Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial | Q44457418 | ||
Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer | Q44572711 | ||
Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study | Q46473453 | ||
P433 | issue | 4 | |
P921 | main subject | colorectal cancer | Q188874 |
capecitabine | Q420207 | ||
oxaliplatin | Q422327 | ||
P304 | page(s) | 431-435 | |
P577 | publication date | 2007-01-01 | |
P1433 | published in | Medical Oncology | Q2152666 |
P1476 | title | Capecitabine plus oxaliplatin (xelox) in the treatment of chemotherapy-naive patients with metastatic colorectal cancer | |
P478 | volume | 24 |
Q42059647 | Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected pulmonary metastases from colorectal cancer |
Q43227528 | Bevacizumab plus irinotecan-based therapy in metastatic colorectal cancer patients previously treated with oxaliplatin-based regimens. |
Q38121955 | DNA interstrand cross-link repair: understanding role of Fanconi anemia pathway and therapeutic implications |
Q38081864 | Management of advanced colorectal cancer, Part 1. |
Q37839084 | XELOX in colorectal cancer: a convenient option for the future? |
Search more.